Avalon GloboCare granted Chinese patent for CAR-T/NK cell technology; term 20 years

Avalon GloboCare Corp.

Patent CN 114502188 B issued by CNIPA, effective April 4, 2025, with 20-year protection.
Co-developed with Hong Kong-based Arbele Limited; covers bispecific anti-CD19xCD22 CAR and localized cytokine induction.
Enhances expansion, manufacturing, survival, and efficacy of CAR-T and CAR-NK cells.
Adds to existing U.S. and PCT protections, strengthening global IP portfolio for cell-based immunotherapy.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-25-030435
form_type: 8-K
ticker: ALBT
cik: 0001630212
company_name: Avalon GloboCare Corp.
filed_at: 2025-04-10T23:59:59+00:00
discovered_at: 2026-05-14T18:02:49.125941+00:00
generated_at: 2026-05-23T17:16:59.846441+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-25-030435
json_url: https://secwatch.observer/filing/0001213900-25-030435.json
markdown_url: https://secwatch.observer/filing/0001213900-25-030435.md
text_url: https://secwatch.observer/filing/0001213900-25-030435.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1630212/000121390025030435/0001213900-25-030435-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1630212/000121390025030435/ea0237706-8k_avalon.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001213900-25-030435

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.